Showing results (121-130 of 180) with videos related to
Sort By:
Pageof 18
Drugs|April 27, 2016
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in MyelomaPhilippe Moreau, Niels W C J van de Donk, Jesus San Miguel, et al.The Lancet. Haematology|July 5, 2016
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trialGordon Cook, A John Ashcroft, David A Cairns, et al.The Lancet. Oncology|July 21, 2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialGareth J Morgan, J Anthony Child, Walter M Gregory, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2019
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple MyelomaSam H Ahmedzai, John A Snowden, Andrew John Ashcroft, et al.Leukemia|May 4, 2023
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.British Journal of Haematology|March 2, 2021
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON studyMarquita Camilleri, Maria Cuadrado, Elizabeth Phillips, et al.Genes, Chromosomes & Cancer|October 8, 2014
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myelomaEileen M Boyle, Paula Z Proszek, Martin F Kaiser, et al.Blood|August 20, 2025
Challenging the Concept of Functional High-Risk Myeloma through Transcriptional and Genetic ProfilingSina Alexandra Beer, David A Cairns, Charlotte Pawlyn, et al.British Journal of Haematology|February 23, 2023
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real-world multicentre UK retrospective analysisAnnabel McMillan, Supratik Basu, Kamaraj Karunanithi, et al.Haematologica|September 17, 2016
High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow TransplantationGordon Cook, Simona Iacobelli, Anja van Biezen, et al.Pageof 18